日韩精品久久一区二区三区_亚洲色图p_亚洲综合在线最大成人_国产中出在线观看_日韩免费_亚洲综合在线一区

Global EditionASIA 中文雙語Fran?ais
Business
Home / Business / Companies

Drugmakers increasingly looking abroad

By LIU ZHIHUA | China Daily | Updated: 2021-07-09 10:05
Share
Share - WeChat
Employees conduct a biopharmaceutical experiment at the Innovative Institute of Nanjing Oncoly Biomedical Technology in Jiangsu province. [Provided to China Daily]

Innovation, talent recruitment and retainment all key to worldwide success

Chinese startup Jacobio Pharmaceuticals, founded in 2015, recently received a $20 million milestone payment from global pharmaceutical giant AbbVie, marking the first milestone payment following the initial upfront fee of $45 million at the outset of Jacobio and AbbVie's collaboration inked in 2020.

The Hong Kong-listed startup is mainly engaged in the research and development of new drugs at the clinical stage. Its main drug development projects include JAB-3068 and JAB-3312.

The milestone payment was triggered by the inoculations of the first two patients in the Phase-1/2 clinical trial of its SHP2 inhibitor JAB-3312 in combination with PD-1 antibody pembrolizumab and MEK inhibitor binimetinib, respectively.

SHP2 is an oncoprotein associated with multiple cancers, as well as a potential immunomodulator. Inhibiting SHP2 activity is therefore of significant therapeutic interest as it can potentially reduce cancer cell growth and modulate immune responses to generate antitumor activities.

Jacobio is just one of an emerging group of Chinese pharmaceutical companies with ambitions to rely on in-house discoveries and develop global-standard first-in-class and best-in-class therapies. Such companies are mostly biotech and biopharmaceutical startups.

Many of them have been able to out-license their innovative products to big-name pharmaceutical giants rather than focusing on in-licensing.

Jacobio entered into a licensing agreement with AbbVie in May 2020 to develop and commercialize SHP2 inhibitors, including JAB-3068 and JAB-3312.

According to the collaboration agreement, AbbVie will be granted an exclusive license to the SHP2 portfolio. Jacobio will continue to conduct early global clinical trials of JAB-3068 and JAB-3312 inhibitors, while AbbVie will cover the R&D expenses.

Upon completion of the trials, AbbVie will be in charge of global development and commercialization. Jacobio will exclusively develop and commercialize the SHP2 inhibitors in the Chinese mainland, Hong Kong and Macao. Jacobio will also receive royalties from AbbVie from global sales.

Wang Yinxiang, chairman and CEO of Jacobio, said the company is the second drug developer in the world to engage in clinical development of an SHP2 inhibitor drug candidate, following Novartis.

JAB-3068 received investigational new drug approval from the US Food and Drug Administration to enter clinical development in January 2018.

JAB-3312 received investigational new drug approval from both the USFDA and China's National Medical Products Administration in 2019.

As of late June, there were only six companies worldwide with SHP2 inhibitors undergoing clinical trials, Wang said.

"When establishing the company, it was clear for us that we must focus on the global market, and to that end, only global-standard first-in-class drugs, rather than 'me too' approaches, will work. It will be of limited value for Chinese companies to develop fast-follower drugs, and for the next decade, opportunities will mainly be for companies that develop global-standard first-in-class drugs," he said.

Since embarking on the collaboration, the company has been working with AbbVie to accelerate the global development of its SHP2 inhibitors in clinical trials via either monotherapy or in combination therapy modalities at more than 30 sites globally.

The company has several projects to file for investigational new drug approvals between 2021 and 2022, Wang said.

According to Liu Jubo, CEO of Chinese biologics company Evive Biotech, the nation's pharmaceutical industry has been shifting from mainly producing generics to innovation-driven novel drug development, and strong independent R&D capability will be the core competence of companies seeking to achieve sustainable growth or expand their global footprint.

Evive recently filed its Biologics License Application for Ryzneuta (also known as F-627) with the USFDA, following successful conclusion of global Phase-3 clinical trials that met primary and secondary endpoints.

1 2 Next   >>|
Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US
CLOSE
 
主站蜘蛛池模板: aa国产视频一区二区 | 97精品国产 | 欧美成人免费全网站大片 | 亚洲国产视频网站 | 一区在线播放 | 日日日日干 | 国产精品爱久久久久久久电影 | 亚洲国产精品久久久 | 国产高清在线精品 | 精品一区二区三区在线视频 | 六月综合激情 | 一区精品视频 | 加勒比AV一本大道香蕉大在线 | 国产人成久久久精品 | 天天干天天摸 | 久久精品这里是免费国产 | 日本香港三级和澳门三级 | 亚洲九九 | 午夜激情视频在线 | 中文字幕亚洲一区二区三区 | 日韩欧美色综合 | 色偷偷综合| 视频一区二区在线观看 | 国产精品a久久久久 | 天天天天 | 国产福利在线播放 | 欧美一区二区三区视频 | 久久激情综合色丁香 | 青青热久久国产久精品秒播 | 亚洲一区二区三区在线 | 精品女同一区二区三区免费播放 | 亲爱的热爱的电视剧免费观看 | 色老头久久网 | 亚洲人成在线精品 | 亚洲zscs综合网站 | 一级黄色免费毛片 | 91麻豆国产极品在线观看洋子 | 不卡中文字幕在线 | 久在线播放 | 青青草成人免费视频在线 | 国产一区二区精品丝袜 |